Bibliography
- Reardon DA, Wen PY, Desjardins A, et al. Glioblastoma multiforme: an emerging paradigm for anti-VEGF therapy. Expert Opin Biol Ther 2008;8(4):541-53
- Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-8
- Stupp R, Mason WP, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
- Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66(8):1258-60
- Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9
- Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
- Chen C, Silverman DHS, Geist C, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25(30):4714-21
- Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology 2008;70:779-87
- Cloughsey TF, Prados MD, Mikkelsen T, et al. A phase II randomized non-comparative trial of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent treatment refractory glioblastoma. J Clin Oncol 2008;26(15S):91s
- Batchelor TT, Sorensen AG, diTomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
- Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11(1):69-82
- Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10
- Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-36
- Batchelor TT, Gilbert M, Supko JG, et al. Phase II study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol 2004;6:21-7
- Prados MD, Lamborn K, Yung WKA, et al. A phase II trail of irinotecan (CPT-11) in patients with recurrent malignant glioma: a NABTC study. Neuro Oncol 2006;8(2):189-93
- Kerbel R, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20(1-2):79-86
- Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8-14
- Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24(20):3293-8
- Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Neuro Oncol 2005;7(3):369